{"id":"W4413394227","doi":"10.1093/ehjcvp/pvaf064","title":"Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF","year":2025,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Montreal Heart Institute; Health Care Foundation","funders":"American Regent; National Institutes of Health; Novo Nordisk; University of Glasgow; ARCA Biopharma; LivaNova; Boston Scientific Corporation; Alexion Pharmaceuticals; Novartis Portugal; Alnylam Pharmaceuticals; Idorsia Pharmaceuticals; British Heart Foundation; Brigham and Women's Hospital; Intas Pharmaceuticals; Eli Lilly and Company; AstraZeneca; Bayer; Amgen; American Heart Association","keywords":"Medicine; Valsartan; Sacubitril, Valsartan; Sacubitril; Internal medicine; Clinical endpoint; Enalapril; Ejection fraction; Logistic regression; Cardiology; Quality of life (healthcare); Heart failure; Clinical trial; Angiotensin-converting enzyme; Blood pressure","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002792945,0.0003444156,0.0009720878,0.0002939686,0.0002947308,0.00008593557,0.0001177543,0.00005038193,0.00001958443],"category_scores_gemma":[0.00008665326,0.0002256834,0.0003613153,0.0004124871,0.0001689977,0.0002243523,0.00008396448,0.00048345,0.000002711828],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001021126,"about_ca_system_score_gemma":0.0001660204,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002043722,"about_ca_topic_score_gemma":0.00002618287,"domain_scores_codex":[0.9963469,0.001470363,0.000669129,0.0004218774,0.0007383082,0.0003534239],"domain_scores_gemma":[0.9987317,0.00009212381,0.0001802864,0.0004633731,0.0003015623,0.0002308954],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001549672,0.00056398,0.9662499,0.0003427477,0.003692314,0.0001688402,0.0005171885,0.0004735255,0.008361511,0.00004623637,0.001296616,0.01673742],"study_design_scores_gemma":[0.01410153,0.0002821153,0.9757522,0.0008519653,0.000659885,0.00007424861,0.00008179279,0.0002158362,0.0007181513,0.00001231732,0.007013205,0.0002367289],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837297,0.01024122,0.003426612,0.001190188,0.0001928144,0.001057778,0.00001399118,0.00003165104,0.0001160067],"genre_scores_gemma":[0.9952658,0.001260052,0.001895071,0.001210705,0.0001700912,0.000005611449,0.000007520295,0.00006230156,0.0001228064],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01650069,"threshold_uncertainty_score":0.92031,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1390294972912309,"score_gpt":0.3345118815845112,"score_spread":0.1954823842932804,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}